Allergan tries to lure Inamed from Medicis deal with sweeter $3.2bn offer
This article was originally published in Clinica
Executive Summary
Allergan, the diversified healthcare company best known in consumer circles for its Botox antiwrinkle treatment, may have triggered a bidding war for Inamed after it proposed to acquire the breast implant maker for $3.2bn, outdoing an earlier offer made by Medicis Pharmaceuticals.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.